Edition:
United States

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

61.56USD
12 Nov 2018
Change (% chg)

$-1.92 (-3.02%)
Prev Close
$63.48
Open
$63.44
Day's High
$63.44
Day's Low
$61.49
Volume
751,311
Avg. Vol
745,944
52-wk High
$78.36
52-wk Low
$61.06

Chart for

About

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $33,780.31
Shares Outstanding(Mil.): 532.14
Dividend: 0.19
Yield (%): 1.20

Financials

  BAX.N Industry Sector
P/E (TTM): 19.27 31.34 29.57
EPS (TTM): 3.29 -- --
ROI: 12.39 12.97 12.77
ROE: 19.36 15.21 14.47

Smiths and ICU Medical healthcare merger talks collapse

British engineering firm Smiths Group Plc said on Thursday talks with U.S.-based ICU Medical Inc over a possible 7 billion pound-plus ($9.2 billion) merger of their healthcare businesses had fallen through.

Sep 13 2018

UPDATE 1-Smiths Group, ICU Medical close to abandoning healthcare merger -Sky News

Aug 7 British engineering firm Smiths Group Plc is close to abandoning talks with U.S.-based ICU Medical Inc over a 7 billion pound ($9 billion) merger of their healthcare divisions, Sky News reported on Monday.

Aug 07 2018

BRIEF-Baxter Expects Sales To Grow ~5 Pct On Compounded Annual Basis At Constant Currency Rates From 2018 To 2023

* BAXTER HIGHLIGHTS BUSINESS STRATEGIES AND INNOVATION AT 2018 INVESTOR CONFERENCE

May 21 2018

BRIEF-Baxter Announces U.S. FDA Clearance Of New Spectrum IQ Infusion System

* BAXTER ANNOUNCES U.S. FDA CLEARANCE OF NEW SPECTRUM IQ INFUSION SYSTEM Source text for Eikon: Further company coverage:

May 14 2018

Earnings vs. Estimates